country

Change Language

EN - English
FR - Français
DE - Deutsch
ES - Español
JA - 日本語
KO - 한국어

Country or Region:

United States

Product Name	Size / Unit Price	Qty

Total: USD 0.00 Checkout

Cat. No.: HY-P992541

Copy Link Print Information

IBI3003

IBI3003 is a trispecific antibody targeting GPRC5D/BCMA/CD3. IBI3003 can redirect T cells to BCMA/GPRC5D-expressing multiple myeloma cells. IBI3003 is designed to overcome single tumor antigen escape caused by low expression of BCMA and GPRC5D. IBI3003 can be used in research on relapsed/refractory multiple myeloma.

연구목적의 판매만을 진행합니다. 환자를 대상으로 한 판매는 하지 않습니다.

보관:

Please store the product under the recommended conditions in the Certificate of Analysis.

IBI3003 Chemical Structure

Amount: USD 0.00

* 장바구니에 담기 전 물품의 수량을 선택해 주십시오.

Use of MCE Products

Strong Fluorescence Signal / Multi-Disciplinary Applications / High Fluorescence Specificity

Biological Activity
- 제품 설명
- Species Reactivity
- In Vitro
- Target
- Conjugated
- 신청
Chemical Information
순도&문서
References
Calculators
Help & FAQs
Classifications
Bioz

Biological Activity

제품 설명

Species Reactivity

Human

In Vitro

Anti-cancer

IBI3003 is a trispecific antibody targeting GPRC5D, BCMA, and CD3, designed to counteract single-antigen-mediated tumor escape; it exhibits potent cytotoxic activity against multiple myeloma with low BCMA and GPRC5D expression^[1].

MedChemExpress (MCE) has not independently confirmed the accuracy of these methods. They are for reference only.

Related Protocols :

RNA extraction experimental

Target

GPRC5D & BCMA & CD3

Conjugated

Unconjugated

신청

ELISA, FACS, Functional assay

Chemical Information

SMILES

[IBI3003]
보관

Please store the product under the recommended conditions in the Certificate of Analysis.

순도&문서

Inhibitory Antibodies User Guide (603 KB)

References

[1]. Li J, et al. Initial Results of the first-in-human Phase 1 study of IBI3003, a novel trispecific antibody targeting GPRC5D, BCMA and CD3, in patients with relapsed or refractory multiple myeloma. Blood. 2025;146(Supplement 1):702.

[2]. van de Donk N W C J. Dual-antigen-targeting T-cell immunotherapies in MM: circumventing tumor heterogeneity and preventing antigen escape. Blood. 2026;147(19):2176-2193.

Calculators

몰농도 계산기

Mass (g) = Concentration (mol/L) × Volume (L) × Molecular Weight (g/mol)

Mass Mass

Concentration Concentration

Volume Volume

Molecular Weight Molecular Weight

농도 희석 계산기

Concentration _(start) × Volume _(start) = Concentration _(final) × Volume _(final)

Concentration _(start) Concentration _(start)

Volume _(start) Volume _(start)

Concentration _(final) Concentration _(final)

Volume _(final) Volume _(final)

Help & FAQs

How should lyophilized recombinant proteins be reconstituted and stored?

1. Before opening the cap, centrifuge the vial at 13000 rpm for 20-30 seconds. This step will ensure that any lyophilized powder that may have adhered to the cap or walls is collected at the bottom of the vial, minimizing the risk of product loss.

Bioz

Keywords

MOQ

Minimum order quantity

100 mg

견적 받기 해외재고보유

Other size

견적 받기